Bone drug tested to save knees after ACL injury – but trial stalls

NCT ID NCT05204836

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested whether a single infusion of zoledronic acid, a drug used for osteoporosis, could improve bone health and slow joint damage after an ACL tear. Only 4 people were enrolled before the trial was terminated, so the results are very limited. The study aimed to see changes in bone structure and joint health over 6 to 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Zoledronic acid injection

What this could lead to

If this approach worked, it might help prevent long-term joint damage after ACL injuries.

What could go wrong

This was a very small, early-phase trial that was terminated early, so we have little data. The drug also has known side effects like bone pain and kidney issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTERIOR CRUCIATE LIGAMENT TEAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anterior Cruciate Ligament Injuries osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Calgary

    Calgary, Alberta, T2N 1N4, Canada